GB9801870D0 - Vaccine composition - Google Patents

Vaccine composition

Info

Publication number
GB9801870D0
GB9801870D0 GBGB9801870.8A GB9801870A GB9801870D0 GB 9801870 D0 GB9801870 D0 GB 9801870D0 GB 9801870 A GB9801870 A GB 9801870A GB 9801870 D0 GB9801870 D0 GB 9801870D0
Authority
GB
United Kingdom
Prior art keywords
vaccine composition
vaccine
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9801870.8A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RABY Ltd
Original Assignee
RABY Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RABY Ltd filed Critical RABY Ltd
Priority to GBGB9801870.8A priority Critical patent/GB9801870D0/en
Publication of GB9801870D0 publication Critical patent/GB9801870D0/en
Priority to AU22897/99A priority patent/AU2289799A/en
Priority to PCT/GB1999/000287 priority patent/WO1999038529A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GBGB9801870.8A 1998-01-28 1998-01-28 Vaccine composition Ceased GB9801870D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GBGB9801870.8A GB9801870D0 (en) 1998-01-28 1998-01-28 Vaccine composition
AU22897/99A AU2289799A (en) 1998-01-28 1999-01-28 Vaccine composition comprising milled lyophilisate of antigenic whole cells
PCT/GB1999/000287 WO1999038529A1 (en) 1998-01-28 1999-01-28 Vaccine composition comprising milled lyophilisate of antigenic whole cells

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9801870.8A GB9801870D0 (en) 1998-01-28 1998-01-28 Vaccine composition

Publications (1)

Publication Number Publication Date
GB9801870D0 true GB9801870D0 (en) 1998-03-25

Family

ID=10826079

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9801870.8A Ceased GB9801870D0 (en) 1998-01-28 1998-01-28 Vaccine composition

Country Status (3)

Country Link
AU (1) AU2289799A (en)
GB (1) GB9801870D0 (en)
WO (1) WO1999038529A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020009429A1 (en) * 1999-01-29 2002-01-24 Galagen, Inc. Pharmaceutical composition comprising a selected antigen and candida species antigen and methods
LT1212045T (en) 1999-08-24 2016-12-12 Abic Biological Laboratories Ltd. A vaccine composition and method of using the same
US6592869B2 (en) 1999-08-24 2003-07-15 Teva Pharmaceutical Industries, Ltd. Vaccine composition and method of using the same
AUPQ761200A0 (en) * 2000-05-19 2000-06-15 Hunter Immunology Limited Compositions and methods for treatment of mucosal infections
US7914799B2 (en) * 2001-08-27 2011-03-29 Immunitor USA, Inc. Anti-fungal composition
PT1461054E (en) * 2001-12-11 2010-08-09 Pasteur Institut Gram positive bacteria preparations for the treatment of diseases comprising an immune dysregulation
CN101060852A (en) * 2004-08-17 2007-10-24 亨特免疫有限公司 Oral inactivation vaccine and its delivery method
DE102004046391A1 (en) * 2004-09-24 2006-04-06 Bioveta Ag New vaccine for veterinary and human medical prophylaxis and therapy

Also Published As

Publication number Publication date
AU2289799A (en) 1999-08-16
WO1999038529A1 (en) 1999-08-05

Similar Documents

Publication Publication Date Title
GB9806456D0 (en) Vaccine composition
HUP0101047A3 (en) Combined vaccine compositions
HK1105581A1 (en) Vaccine composition
GB9812613D0 (en) Vaccine
GB9910812D0 (en) Vaccine composition
GB9616351D0 (en) Vaccine composition
GB9623233D0 (en) Vaccine composition
GB0027072D0 (en) Vaccine
GB9801870D0 (en) Vaccine composition
GB9802879D0 (en) Vaccine composition
GB9806455D0 (en) Vaccine composition
GB9807805D0 (en) Vaccine
GB9820956D0 (en) Vaccine
GB9821821D0 (en) Schistomiasis vaccine
GB9802544D0 (en) Vaccine
GB9807933D0 (en) Vaccine
GB9822712D0 (en) Vaccine
GB9828035D0 (en) Vaccine
GB9822703D0 (en) Vaccine
GB9812773D0 (en) Vaccine
GB9812228D0 (en) Vaccine
GB9811954D0 (en) Vaccine
GB9802543D0 (en) Vaccine
GB9802650D0 (en) Vaccine
GB9822709D0 (en) Vaccine

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)